Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro

Hur, Jong Moon; Shim, Joong Sup; Jung, Hye Jin; Kwon, Ho Jeong

doi:10.1038/emm.2005.18

Cited by 82 publications

(56 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The formation of vascular-like structures by HUVECs on growth factor-reduced Matrigel was performed as previously described Hur et al, 2005). Twenty-four well culture plates were coated with Matrigel according to the manufacturer's instructions.…”

Section: Tube Formation Assaymentioning

confidence: 99%

Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells

Namkoong

Lee²,

Kim³

et al. 2005

Exp Mol Med

117

View full text Add to dashboard Cite

Prostaglandin E 2 (PGE 2 ), a major product of cyclooxygenase, has been implicated in modulating angiogenesis, vascular function, and inflammatory processes, but the underlying mechanism is not clearly elucidated. We here investigated the molecular mechanism by which PGE2 regulates angiogenesis. Treatment of human umbilical vein endothelial cells (HUVEC) with PGE 2 increased angiogenesis. PGE 2 increased phosphorylation of Akt and endothelial nitric oxide synthase (eNOS), eNOS activity, and nitric oxide (NO) production by the activation of cAMP-dependent protein kinase (PKA) and phosphatidylinositol 3-kinase (PI3K). Dibutyryl cAMP (DB-cAMP) mimicked the role of PGE 2 in angiogenesis and the signaling pathway, suggesting that cAMP is a down-stream mediator of PGE2. Furthermore, PGE2 increased endothelial cell sprouting from normal murine aortic segments, but not from eNOS-deficient ones, on Matrigel. The angiogenic effects of PGE 2 were inhibited by the inhibitors of PKA, PI3K, eNOS, and soluble guanylate cyclase, but not by phospholipase C inhibitor. These results clearly show that PGE2 increased angiogenesis by activating the NO/cGMP signaling pathway through PKA/PI3K/Akt-dependent increase in eNOS activity.

show abstract

Section: Tube Formation Assaymentioning

confidence: 99%

Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells

Namkoong

Lee²,

Kim³

et al. 2005

Exp Mol Med

117

View full text Add to dashboard Cite

show abstract

“…12,13 Cryptotanshinone (CPT), one of the major representative components isolated from Danshen, has been reported to possess various pharmacological activities, such as anti-inflammatory, anti-angiogenic, anti-oxidative, anti-obese, and anti-diabetic functions. [14][15][16][17] Recently, CPT has also been reported to have obvious antitumor activity in a variety of cancer cells, including prostate carcinoma, hepatocarcinoma, rhabdomyosarcoma and melanoma cells. [18][19][20][21][22][23] In breast carcinoma cells, CPT has been shown to inhibit MCF7 cell proliferation by suppressing mTOR mediated CyclinD1 expression and Rb phosphorylation that lead to MCF7 cell apoptosis by inducing stress in the endoplasmic reticulum (ER).…”

Section: Introductionmentioning

confidence: 99%

Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling

Wang

Liu

et al. 2014

Cancer Biology & Therapy

View full text Add to dashboard Cite

y These authors contributed equally to this work.Keywords: breast cancer, cryptotanshinone, estradiol, estrogen receptor Abbreviations: ER, estrogen receptor; CPT, cryptotanshinone; EREs, estrogen-responsive elements; SERM, selective estrogen receptor modulator; CADD, computer-aided drug design; ROS, reactive oxygen species.Estrogen receptor (ER) is a major therapeutic target for the treatment of breast cancer, because of the crucial role of estrogen signaling deregulation in the development and progression of breast cancer. In this study, we report the identification of a novel ERa binding compound, cryptotanshinone (CPT), by screening the CADD database. We also show that CPT effectively inhibits estrogen-induced ER transactivation and gene expression of ER target genes. Furthermore, we showed that CPT suppressed breast cancer cell growth mainly in an ERa dependent manner. Finally, we confirmed the potential therapeutic efficiency of CPT using xenograft experiments in vivo. Taken together, our results describe a novel mechanism for the anticancer activity of CPT and provide supporting evidence for its use as a potential therapeutic agent to treat patients with ERa positive breast cancer.

show abstract

“…Tanshinones are the major component of Danshen, the dried roots of Salvia miltiorrhiza Bunge (Labiatae) that is used as a drug in traditional Chinese medicine (Hazra et al, 2004;Hur et al, 2005). Tanshinones have been widely used to treat menorrhalgia, insomnia, coronary disease, and cardiovascular disease (Takahashi et al, 2002;Han et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1

Kwak

Yang²,

Ha³

et al. 2006

Exp Mol Med

View full text Add to dashboard Cite

show abstract

Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro

Cited by 82 publications

References 24 publications

Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells

Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells

Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling

Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1

Contact Info

Product

Resources

About